<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662727</url>
  </required_header>
  <id_info>
    <org_study_id>ESMR-RCT-IL</org_study_id>
    <nct_id>NCT00662727</nct_id>
  </id_info>
  <brief_title>Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris</brief_title>
  <official_title>Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medispec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medispec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low intensity shockwaves have been proven in animal studies to induce local growth of new&#xD;
      blood vessels from existing ones.&#xD;
&#xD;
      The hypothesis of this study is that shockwave therapy could improve the symptoms of patients&#xD;
      with refractory angina not amenable to revascularization with angioplasty or bypass surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to myocardial&#xD;
      ischemic tissue. Shockwaves are created by a special generator and are focused using a&#xD;
      shockwave applicator device. The treatment is guided by standard echocardiography equipment.&#xD;
      The shockwaves are delivered in synchronization with Patient R-wave to avoid arrhythmias. The&#xD;
      treatment is painless.&#xD;
&#xD;
      At first, the patient undergoes stress- SPECT testing to identify the ischemic areas.&#xD;
      Following that, the same area is localized by the ultra-sound device and the shockwaves are&#xD;
      focused to the ischemic area. Several treatments are required for optimal results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Exercise Time</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SPECT</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AP-CCS</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Refractory Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A - Treatment group. Patients in this group receive actual shockwave therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)</intervention_name>
    <description>Energy Density - 0.09 mJ/mm2</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Cardiospec</other_name>
    <other_name>ESMR therapy</other_name>
    <other_name>Extracorporeal Shockwave Myocardial Revascularization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with chronic stable angina pectoris.&#xD;
&#xD;
          -  Documented myocardial segments with reversible ischemia&#xD;
&#xD;
          -  AP CCS class of III-IV.&#xD;
&#xD;
          -  Stable dosage of medication used to treat angina for at least 6 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Exercise tolerance time &lt; 10 min (modified Bruce)&#xD;
&#xD;
          -  Two ETT tests results (within two weeks) averaging no more than 25% of their mean&#xD;
&#xD;
          -  Documented epicardial coronary artery disease not amenable to angioplasty or CABG.&#xD;
&#xD;
          -  Signed an IRB approved informed consent form.&#xD;
&#xD;
          -  Life expectancy of &gt;12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intraventricular thrombus&#xD;
&#xD;
          -  Malignancy in the area of treatment&#xD;
&#xD;
          -  Severe COPD&#xD;
&#xD;
          -  No smoking during the study procedure&#xD;
&#xD;
          -  MI less &lt;3 months prior to treatment&#xD;
&#xD;
          -  Severe Valvular disease&#xD;
&#xD;
          -  Child bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>February 17, 2013</last_update_submitted>
  <last_update_submitted_qc>February 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extracorporeal Shockwave Therapy</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Refractory Angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

